Apreo Health

• 12/08/2025
• Series B
• $130,000,000

Apreo Health is an emerging clinical-stage medical device company dedicated to restoring health and quality of life to patients afflicted with severe emphysema, an advanced form of Chronic Obstructive Pulmonary Disease (COPD).

In 2018 COPD was the second leading cause of death in United States of America(1) behind Ischemic Heart Disease, with over 8,000 deaths due to emphysema in 2023(2).

Apreo Health’s first product, the Apreo BREATHE Airway Scaffold is a novel implant designed to gently release air trapped in affected hyper-inflated lungs.

Apreo Health is dedicated to pioneering safe, transformative solutions for lung disease. We serve patients with passion, integrity and a commitment to restoring their health and quality of life.

Apreo is a privately held company headquartered in Menlo Park, CA., USA.

The BREATHE Airway Scaffold is an investigational device and is limited to Federal (or US) investigational use. It is to be exclusively used in clinical investigations.

1 - https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death
2 - https://wonder.cdc.gov/controller/datarequest/D158;jsessionid=D4265629C7ECA176FDA9D2256A45

---

---